Tempus AI stock (NASDAQ: TEM) represents shares in Tempus AI, Inc., a leading healthcare technology company that leverages artificial intelligence to advance precision medicine. Tempus builds one of the world’s largest libraries of multimodal clinical, molecular, and imaging data, powering AI-enabled diagnostics, algorithmic tests (Algos), clinical trial matching (Trials), data licensing (Insights), and platforms like Hub and Lens for physicians, researchers, and biopharma partners. The stock provides investors exposure to the rapidly growing intersection of AI and personalized healthcare, with applications in oncology, cardiology, and beyond—driving better patient outcomes through data-driven insights and therapeutic discovery.
Is Tempus AI Stock Free or Paid?
Tempus AI stock is a publicly traded equity on the NASDAQ exchange, meaning it is neither “free” nor subscription-based like software. Investors purchase shares through brokerage accounts (Robinhood, Fidelity, etc.) at the current market price, with no recurring fees beyond standard trading commissions or platform costs. Ownership grants exposure to the company’s performance but requires capital to buy shares—no free access exists to “use” the stock itself. Tempus itself operates a B2B model with paid services for healthcare providers and pharma companies, but the stock is simply an investment vehicle available to anyone with a brokerage account.
Tempus AI Stock Pricing Details
Tempus AI stock pricing is determined by market dynamics on NASDAQ (ticker: TEM), not subscription plans. There are no monthly/yearly “plans”—investors buy shares at the prevailing market price. Below is a snapshot of key stock metrics and typical investment considerations (as of mid-February 2026):
| Plan Name / Metric | Price (Approximate / Market) | Main Features | Best For |
|---|---|---|---|
| Current Market Price | ~$50–$51 per share | Real-time trading, full ownership rights, dividends (none currently), voting rights | Individual investors, long-term holders betting on AI healthcare growth |
| 52-Week Range | $36.22 (low) – $104.32 (high) | Volatility exposure, potential entry/exit points based on market cycles | Swing traders, value seekers looking for dips |
| Analyst Average Target (2026) | ~$87–$89 (consensus) | Implied upside from current levels, based on 13+ analysts (high $105, low $70) | Growth-oriented investors, portfolio allocators |
| Market Capitalization | ~$9–$10 billion | Enterprise scale, liquidity on NASDAQ, institutional interest | Diversified portfolios, sector-focused funds |
Also Read-AI Checker Free, Alternative, Pricing, Pros and Cons
Best Alternatives to Tempus AI Stock
Investors seeking exposure to AI in healthcare or precision medicine can consider these comparable publicly traded companies with varying focuses on data, diagnostics, or AI applications.
| Alternative Tool Name | Free or Paid | Key Feature | How it Compares to Tempus AI Stock |
|---|---|---|---|
| Guardant Health (GH) | Public stock (NASDAQ: GH) | Liquid biopsy, cancer screening, real-world data | Strong in oncology diagnostics; more focused on blood-based tests vs. Tempus’s broad multimodal data library |
| Exact Sciences (EXAS) | Public stock (NASDAQ: EXAS) | Non-invasive cancer screening (Cologuard), molecular diagnostics | Established revenue in colorectal screening; less AI-heavy but proven commercial traction compared to Tempus |
| Illumina (ILMN) | Public stock (NASDAQ: ILMN) | Genomic sequencing hardware and services | Leader in sequencing tech; upstream supplier to Tempus-like companies but hardware-focused vs. Tempus’s data/AI platform |
| Personalis (PSNL) | Public stock (NASDAQ: PSNL) | Comprehensive genomic profiling, MRD testing | Niche in advanced cancer genomics; smaller scale but similar precision medicine play |
| Qiagen (QGEN) | Public stock (NYSE: QGEN) | Molecular diagnostics tools, sample prep | Global reach in diagnostics; more traditional lab tools vs. Tempus’s pure AI-driven approach |
| Twist Bioscience (TWST) | Public stock (NASDAQ: TWST) | Synthetic DNA for research and therapeutics | Enables genomics innovation; complementary but upstream in the supply chain compared to Tempus |
Pros and Cons of Tempus AI Stock
Tempus AI stock offers compelling exposure to the booming AI-healthcare convergence, but it carries typical biotech/tech risks.
Pros:
- Strong positioning in precision medicine with one of the largest multimodal datasets, fueling AI diagnostics and pharma partnerships.
- Robust revenue growth trajectory (projected 25%+ in 2026) and expanding contract value in data licensing and trials.
- Analyst consensus leans positive with significant upside potential from current levels based on 2026 forecasts.
- Benefits from secular trends in AI adoption, oncology innovation, and personalized care demand.
- NASDAQ listing provides liquidity and institutional visibility for long-term investors.
Cons:
- High volatility typical of growth healthcare stocks—recent quarters show sharp swings tied to earnings sentiment.
- Ongoing net losses and negative earnings reflect heavy R&D reinvestment, delaying profitability.
- Valuation appears stretched on forward multiples for some investors amid biotech sector headwinds.
- Competitive landscape in AI diagnostics and data platforms requires continued execution to maintain edge.
- Macro risks (interest rates, regulatory changes in healthcare/AI) can impact sentiment and price.